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ABSTRACT  1 
Background: Elevated circulating cystathionine levels are related to atherosclerotic 2 
cardiovascular disease, a leading cause of death globally.  3 
Objective: We investigated whether plasma cystathionine was associated with mortality in 4 
patients with suspected or established coronary heart disease (CHD).  5 
Design: Data from two independent cohorts of patients with suspected stable angina pectoris 6 
(SAP) (3033 patients; median 10.7 years follow-up; 648 deaths) or acute myocardial 7 
infarction (AMI) (3670 patients; median 7.0 years follow-up; 758 deaths) were included. 8 
Hazard ratios (HRs) with 95% confidence intervals (CIs) per 1-SD increment of log-9 
transformed cystathionine were calculated using Cox-regression modelling. Endpoint data 10 
was obtained from National Health Registries. 11 
Results: Among patients with SAP, there was a positive association between plasma 12 
cystathionine and death (age and sex adjusted HR [95% CI] per SD: 1.23 [1.14, 1.32], 1.29 13 
[1.16, 1.44] and 1.17 [1.05, 1.29] for total, cardiovascular and non-cardiovascular mortality, 14 
respectively). Corresponding risk estimates were 1.28 (1.19, 1.37) for all-cause, 1.33 (1.22, 15 
1.45) for cardiovascular and 1.19 (1.06, 1.34) for non-cardiovascular death among AMI 16 
patients. In both cohorts, estimates were slightly attenuated after multivariate adjustments for 17 
established CHD risk factors. Subgroup analyses showed that the relationship between 18 
cystathionine and all-cause mortality in SAP patients was stronger among non-smokers, and 19 
those with lower plasma concentration of pyridoxal-5-phosphate (P-interaction≤0.03 for 20 
both).  21 
Conclusions: Elevated plasma cystathionine is associated with both cardiovascular and non-22 





effects of high cystathionine with lifestyle factors and impaired vitamin B-6 status on 24 
mortality need further investigation. 25 




























Atherosclerosis, characterized by the deposition of plaques inside the arterial wall is the major 50 
cause of cardiovascular disease (CVD) and CVD death (1-3).  Cystathionine is a metabolite of 51 
the trans-sulfuration pathway formed during the pyridoxal 5´-phosphate -dependent (PLP) 52 
conversion of methionine (Met) to cysteine (4) and has been linked to oxidative damage (5,6), 53 
and impaired endothelial function (4,6), which are key players in the development of early 54 
atherosclerotic lesions (1). Interestingly, circulating cystathionine has been positively related 55 
with several factors involved in atherogenesis, including higher age (7,8), impaired kidney 56 
function (9), body mass index (BMI) (8) and unfavorable lipid profile (8), as well as with 57 
various pathological conditions, especially CVD (8).  Moreover, elevated plasma 58 
cystathionine levels were predictive of acute myocardial infarction risk (10) and stroke events 59 
(6) among patients with coronary heart disease (CHD) in the same cohorts or a subsample of 60 
cohorts as those currently investigated. 61 
Taken together, these observations suggest that cystathionine is associated with 62 
atherosclerotic CVD, and thus may affect survival. Indeed, the hepatic activity of 63 
cystathionine biosynthesizing enzyme, cystathionine β-synthase (CBS) is reported to be 64 
significantly lower in long-lived naked mole-rat than normal mouse (11).  Others found that 65 
the deficiency of cystathionine γ-lyase (CSE), the principal enzyme involved in cystathionine 66 
catabolism (5) was associated with increased mortality in mice subjected to 67 
ischemia/reperfusion injury (12). Further, Met restriction, which is well known for life-68 
extending effects (13), has been shown to decrease the level of CBS protein (14). However, 69 
these observations are based on measurements of gene expressions or enzymatic activities, 70 
and only one small study in humans (with sepsis) found that systemic concentrations of 71 





We investigated the association between plasma cystathionine and the risk of all-73 
cause, cardiovascular and non-cardiovascular mortality using data from two independent 74 




























Study cohorts  99 
The present study consisted of patients from two large independent cohorts (Supplemental 100 
Figure 1) : the Western Norway Coronary Angiography Cohort (WECAC) with 4164 patients 101 
who were undergoing coronary angiography due to suspected stable angina (SAP) at 102 
Haukeland (n=3413) or Stavanger (n=751) University Hospitals, Norway in the period 2000-103 
2004, and have been described in detail elsewhere (16). Approximately 2/3 of these patients 104 
were enrolled in the Western Norway B-vitamin Intervention Trial (WENBIT, 105 
NCT00354081) and randomly received treatments with folic acid plus vitamin B12 and/or 106 
vitamin B6, or placebo (17).  The Norwegian Vitamin Trial (NORVIT, NCT00266487) 107 
included 3749 patients hospitalized for acute myocardial infarction (AMI) (18), who were 108 
randomized to identical interventions with B-vitamins as the patients in WENBIT. In the 109 
current study, we excluded patients without valid measurements on plasma cystathionine, 110 
leaving a total of 3033 and 3670 patients with SAP and AMI, respectively, eligible for the 111 
final analyses. The study met the mandate of the Helsinki Declaration, and was approved by 112 
the regional ethics committee and the Norwegian Data Inspectorate. All study participants 113 
provided written informed consent. 114 
Baseline data and biochemical analyses 115 
The collection of baseline information and biochemical analyses, including handling and 116 
storage of blood samples before analysis, have been reported earlier (16,18).  Briefly, 117 
information about patients’ lifestyle and medical history, including cardiovascular disease risk 118 
factors and medications, were obtained from self-administered questionnaires, and were 119 
validated against hospital records when available.  Hypertension was defined by pre,existing 120 
diagnosis. Current smokers included those with self-reported current smoking, those having 121 





filtration rate (eGFR/1.73m2) was calculated by the Chronic Kidney Disease Epidemiology 123 
Collaboration formula (19).  124 
Plasma concentrations of cystathionine, Met, and total homocysteine (tHcy) were 125 
measured with the use of gas chromatography-tandem mass spectrometry, whereas plasma 126 
PLP, asymmetric dimethylarginine (ADMA), and serum cotinine were determined by liquid 127 
chromatography-tandem mass spectrometry. These analyses were carried out at Bevital AS 128 
laboratory, Bergen, Norway (www.bevital.no). In addition, among patients with SAP, serum 129 
C-reactive protein (CRP) concentrations were measured by an ultrasensitive immunoassay 130 
(Behring nephelometer II system N Latex CRP mono; Behring Diagnostics). Among AMI 131 
patients, we did not have information on CRP.  132 
 133 
Follow-up and study end points 134 
The study subjects were followed-up from enrollment until December 2012 (SAP patients) or 135 
December 2007 (AMI patients). Information on death was obtained from the Cause of Death 136 
Registry at Statistics Norway (www.ssb.no/en). The primary endpoint of interest was all-137 
cause mortality, whereas secondary endpoints were death due to cardiovascular or non-138 
cardiovascular causes. Cardiovascular mortality (ICD-10, I00-I99 or R96) and deaths due to 139 
cancer (ICD-10, C00-C97) were classified according to the 10th Revision of the International 140 
Classification of Disease. 141 
 142 
Statistical analyses  143 
Associations of plasma cystathionine with baseline categorical variables were visualized by 144 
bar charts. Correlation analyses between continuous variables were performed using 145 





Cox proportional hazard regression models were used to estimate the association 147 
between plasma cystathionine and subsequent risk of death during follow up. The hazard 148 
ratios (HRs) and 95% confidence intervals (CI) were reported across quartiles of plasma 149 
cystathionine and per 1 standard deviation (SD) increment of log-transformed plasma 150 
cystathionine. The simple model included age and sex, and the multivariate model also 151 
included current smoking (yes/no), hypertension (yes/no), diabetes mellitus (yes/no), previous 152 
AMI (yes/no), BMI, serum total cholesterol (both continuous) and treatment with folic acid 153 
(yes/no) or vitamin B6 (yes/no). The proportionality of hazards was verified by inspection of 154 
survival plots and calculating Schoenfeld residuals. Potential non-linear associations between 155 
cystathionine and risk of all cause, cardiovascular and non-cardiovascular mortality were 156 
analyzed by generalized additive regression plots, adjusted for age and sex.  157 
Subgroup analyses in both cohorts were performed according to traditional CHD risk 158 
factors and medications at discharge. We previously reported the association between 159 
cystathionine and AMI risk to be particularly strong among patients with low plasma PLP 160 
concentrations (10). Hence, we also examined whether the associations of cystathionine with 161 
mortality was modified by B-vitamin status, including serum folate and cobalamin, and 162 
plasma PLP, as well as according to the study treatment allocation among WENBIT and 163 
NORVIT participants. We also explored the combined influence of vitamin treatment and 164 
baseline vitamin status on risk associations in WENBIT or NORVIT. Tests for effect 165 
modifications were performed by entering interaction product terms to the Cox model, 166 
adjusted for age and sex.  Moreover, sensitivity towards unobserved confounding was 167 
quantified by calculating E-values from the multivariate Cox regression model, according to 168 





All of the computations were performed using software SPSS for Windows (version 170 
23; SPSS IBM, NY, USA) and R (R Development Core Team, version 3.2.1). Probability 171 



























RESULTS  195 
Baseline characteristics  196 
The baseline associations of plasma cystathionine with selected continuous and 197 
categorical variables for both SAP and AMI populations are shown in Figure 1 and 198 
Supplemental Figure 2, respectively and across quartiles of cystathionine in Supplemental 199 
Table 1 (WENBIT patients) and Supplemental Table 2 (NORVIT patients) (10). In both 200 
study populations (Figure 1), plasma cystathionine was positively correlated with age (r= 0.24 201 
and 0.31 for SAP and AMI patients respectively), ADMA (r= 0.16 and 0.07) and inversely 202 
with eGFR levels (r= -0.36 and -0.29). As expected, cystathionine concentrations correlated 203 
positively with concentrations of both plasma Met, and tHcy and negatively with serum folate 204 
and plasma PLP. Moreover, among patients with SAP, plasma cystathionine was related to 205 
higher levels of serum triglycerides and CRP but lower low-density lipoprotein cholesterol 206 
and high-density lipoprotein cholesterol  207 
In addition, in both study cohorts, those with hypertension, diabetes as well as those 208 
who had experienced previous AMI or used angiotensin-converting enzyme inhibitors had 209 
higher, while current smokers had lower plasma cystathionine levels (Supplemental Figure 2).  210 
 211 
Follow‐up and outcomes 212 
The median (interquartile range) follow-up time was 10.7 (2.6) years and 7.0 (1.9) years for 213 
SAP and AMI-patients, respectively. Among patients with SAP, 648 (21.4%) died, of whom 214 
301 and 347 due to cardiovascular and non-cardiovascular causes, respectively. Among 215 
patients with AMI, there were a total of 758 deaths (20.7%): 463 were caused by CVD and 216 
295 by non-CVD causes. 217 
Among patients with SAP, after adjusting for age and sex, higher plasma cystathionine 218 





[1.14,1.32]; P < 0.001). Multivariate adjustments left the risk associations essentially 220 
unaltered (Table 1). Further, the HRs (95% CI) per SD of plasma cystathionine were 1.23 221 
(1.09, 1.40; P=0.001) for cardiovascular and 1.16 (1.03, 1.31; P= 0.01) for non-cardiovascular 222 
death in multivariate model (Table 1). 223 
Met derived homocysteine is the only precursor of cystathionine (4), and elevated 224 
plasma tHcy has been positively associated with mortality risk in coronary artery disease 225 
(CAD) patients (21). Systemic cystathionine concentrations are also found to be elevated in 226 
pathological conditions, including inflammatory (15, 22) and renal disease (9); hence we 227 
additionally included the cystathionine precursors, as well as CRP and eGFR one at a time in 228 
the multivariate model. Including plasma Met plus tHcy, or serum CRP in the model only 229 
slightly attenuated the risk estimates, whereas controlling for eGFR moderately weakened the 230 
relationship between plasma cystathionine and the endpoints (Supplemental Table 3).  231 
Among AMI patients, in age and sex adjusted analysis, HRs (95% CI) per SD 232 
increment of cystathionine were 1.28 (1.19, 1.37; P< 0.001) for all-cause death, 1.33 (1.22, 233 
1.45; P< 0.001) for cardiovascular death and 1.19 (1.06, 1.34; P= 0.003) for non-234 
cardiovascular causes of death (Table 2). In these patients, multivariable adjustments (Table 235 
2) or controlling for metabolic precursors or eGFR only slightly altered the risk associations 236 
(Supplemental Table 3). 237 
We found approximately linear relationship between plasma cystathionine 238 
concentrations and all-cause or CVD mortality in both cohorts, while some deviation from 239 
linearity was observed for the association with non-CVD mortality, especially among patients 240 
with SAP (Figure 2). 241 
We next examined the relationship between plasma cystathionine and cancer related 242 
mortality in both study cohorts (Table 3). Among patients with SAP, 187 (53.9%) of 347 243 





295 non-CVD deaths were due to cancer. Plasma cystathionine was associated with increased 245 
cancer mortality risk in an unadjusted model, but not after adjustment for age and sex (HR 246 
[95% CI] per SD: 1.05 [0.91, 1.22; P=0.51] and 1.06 [0.89, 1.25; P=0.50] in patients with 247 
SAP and AMI, respectively (Table 3). On the other hand, cystathionine showed stronger risk 248 
association with non-CVD mortality in the heterogeneous group of 160 deaths (SAP patients) 249 
and 137 deaths (AMI patients) in whom cancer was not underlying cause of death 250 
(multivariate-adjusted HRs [95% CI] per SD: 1.24 [1.05,1.48; P=0.01] and 1.23 [1.02, 1.47; 251 
P=0.03], respectively) 252 
 253 
Subgroup analyses  254 
Subgroup analyses according to traditional CHD risk factors and systemic B-vitamin status 255 
are presented in Table 4 and according to WENBIT or NORVIT study treatment allocation 256 
and medications at discharge in Supplemental Table 4 and 5, respectively.  257 
Among patients with SAP, the association between cystathionine and all-cause mortality was 258 
stronger in non-smokers and subjects who had PLP below the median (Table 4) (P for 259 
interactions = 0.001 and 0.01, respectively). The interaction remained significant after 260 
multivariate adjustment (data not shown) 261 
In neither cohort did we observe any effect modifications according to other subgroup 262 
parameter (P for interactions > 0.05). 263 
In addition, when exploring PLP subgroups according to folic acid or vitamin B6 264 
treatment, we observed a similar trend towards increased risk with low PLP levels, regardless 265 
of study intervention (Supplemental Table 6).  266 
Sensitivity analyses  267 
To reduce any chance of potential reverse causation, we performed additional sensitivity 268 





SAP and AMI cohorts, respectively). The risk associations were slightly attenuated in the 270 
remaining data set.  In patients with SAP, cystathionine provided multivariate-adjusted HRs 271 
(95% CI) per SD of 1.20 (1.10, 1.31; P< 0.001), 1.23 (1.07, 1.40; P=0.003) and 1.17 (1.04, 272 
1.32; P=0.01) for total, cardiovascular and non-cardiovascular mortality, respectively. 273 
Corresponding risk estimates were 1.16 (1.06, 1.27; P= 0.001), 1.18 (1.04, 1.34; P=0.01) and 274 
1.13 (95% CI: 0.99, 1.30; P=0.06) for AMI patients. 275 
                        Furthermore, application of E-formula revealed high sensitivity of the 276 
observed association between cystathionine and endpoints across both study cohorts, as 277 
reflected by high E-value for the total effect estimate as well as for lower reported CI 278 





















Principal findings 296 
Using two independent, large cohorts of patients with SAP and AMI, we demonstrate that 297 
high plasma cystathionine levels were associated with an increased risk of mortality during 298 
follow-up independent of traditional risk factors, as well as potential confounders. Among 299 
SAP patients, the associations of cystathionine with all-cause mortality tended to be stronger 300 
among non-smokers and those with low plasma PLP levels. 301 
Strengths and limitations  302 
The major strengths of the current study are its long-term prospective design, large sample 303 
sizes, detailed characterization of patients in two independent populations together with 304 
information on outcomes obtained from public national registries. Furthermore, the sensitivity 305 
analyses indicated that the observed results are robust to unobserved cofounding, and 306 
therefore are expected to be reproducible by others with new data (20). 307 
The current study has, however, some limitations. First, high plasma cystathionine may 308 
simply reflect Met and homocysteine surplus (4,22). However, controlling for plasma Met 309 
and tHcy had minimally attenuating effects on our estimates, indicating that the current 310 
findings are largely independent of these metabolic precursors. Second, our results are also 311 
unlikely to be explained by any bias from reverse causality because the estimates were only 312 
slightly attenuated after excluding the first year of follow-up. Third, we were unable to 313 
examine the subtypes of non-cardiovascular causes of death beyond those related to cancer. 314 
This, however, does not detract from our findings on plasma cystathionine and risk of overall 315 
mortality. Fourth, the majority of patients in the current study received study supplementation 316 
with folic acid and/or other B-vitamins, which can affect plasma cystathionine levels (23). 317 
Further, folate has been suggested to regulate tHcy and cystathionine status by inhibiting the 318 





status in the cell and linked to regulation of cholesterol transport (26) as well as immune 320 
activation (27). However, B-vitamin intervention neither appreciably altered risk estimates of 321 
cystathionine when included in the multivariable model nor introduced any significant effect-322 
modifications in subgroup analyses, indicating that supplementation with B-vitamin is 323 
unlikely to explain the observed risk association. Finally, we mainly studied subjects, in 324 
whom the majority being treated with several medications at discharge, and our results thus 325 
may not be applicable to a healthy patient cohort.  326 
Plasma cystathionine and mortality in other epidemiological studies 327 
 Data on circulating cystathionine and poor prognosis are sparse. A study among 35 critically 328 
–ill patients reported higher plasma cystathionine levels in non-survivor group at certain time 329 
points during 28-days follow-up (15).  However, to our knowledge, the present investigation 330 
is the first large-scale patient-based cohort study to reveal such an association. Notably, the 331 
findings were validated in a second patient cohort. 332 
Possible mechanisms  333 
Cystathionine, inflammation and plasma PLP status  334 
High dietary intake of the cystathionine precursor Met in rats has been shown to increase the 335 
levels of the inflammatory marker, C-reactive protein (28), which is associated with an 336 
increased risk of mortality in patients with acute coronary syndrome (29) and in apparently 337 
healthy subjects (30). However, adjusting for CRP in SAP patients did not seem to attenuate 338 
the risk estimates, although cystathionine and CRP were positively correlated at baseline. 339 
Notably, high plasma concentration of CRP has been consistently related to low PLP status in 340 
several studies (31, 32) including patients with SAP (31). Inadequate vitamin B-6 status also 341 
results in decreased cystathionine γ-lyase activity, causing elevation of cystathionine in 342 
plasma (22).  We previously showed that the positive association between cystathionine and 343 





study, a similar trend was seen in relation to mortality risk in PLP subgroup alone or also 345 
those jointly evaluated with B-vitamins treatment. Thus, the low B-6 status, rather than 346 
inflammation, could represent a possible link between CRP and cystathionine metabolism. 347 
Cystathionine, endothelial dysfunction, oxidative stress and smoking status 348 
Plasma cystathionine has been related to endothelial dysfunction and oxidative stress in 349 
previous report (6), which could at least partly account for the adverse prognosis observed in 350 
the current study, particularly regarding cardiovascular mortality. Accordingly, across both 351 
patients with SAP and AMI, plasma cystathionine showed positive associations with ADMA, 352 
an endogenous inhibitor of NO synthase (33). Similar observations have previously been 353 
made in a subset of the current SAP population (6).  Interestingly, despite the occurrence of 354 
high oxidative stress in smokers (34), among SAP patients, elevated plasma cystathionine 355 
concentrations appeared to increase the risk of mortality particularly in non-smokers; 356 
however, putative associations may be masked among smokers, as smoking is the 357 
predominant risk factor for mortality (34). Another possibility is that patients with SAP at 358 
high risk of CVD may have quitted smoking before enrollment. 359 
Cystathionine and renal function  360 
In line with our findings, plasma cystathionine levels are elevated in patients with renal 361 
dysfunction (9), which is a major risk factor of mortality (35). Renal function could thus serve 362 
as potential confounder in our study, as suggested by the attenuation of risk estimates by 363 
adjusting for eGFR in SAP patients. However, a previous study in patients with end-stage 364 
kidney disease found no significant association between plasma cystathionine and adverse 365 
cardiovascular events (36). Further, our cohorts mainly consisted of patients without signs of 366 
severely impaired renal function, as reflected by eGFR levels. Therefore, it is not likely that 367 
our findings are explained solely by renal impairment.  368 





An unexpected finding from our study was the positive association between plasma 370 
cystathionine levels and non-CVD mortality across both cohorts. A nested case-control study 371 
found that high levels of serum cystathionine may be an independent predictor of early 372 
biochemical recurrence and aggressiveness of prostate cancer (37). However, we did not 373 
observe any increased cancer mortality risk according to elevated plasma cystathionine in 374 
either cohort, indicating that cancer is unlikely to have contributed to adverse non-375 
cardiovascular prognosis. On the other hand, cystathionine has been associated with cognitive 376 
decline (38), liver dysfunction (39), asthma (22) as well as sepsis (15). In addition, 377 
experimental studies have demonstrated a link between cystathionine metabolism and 378 
diabetes mellitus (40). It has been suggested that aberrant fluxes through transsulfuration 379 
enzymes may be attributable to the metabolic consequences of some of these diseases (22, 39, 380 
40).  It is therefore interesting that in our recent observation in a subset of SAP patients, 381 
plasma cystathionine associated positively with lanthionine (41), which is an indirect marker 382 
of increased CBS flux and negatively with glutathione (41), indicating impaired CSE 383 
induction (5,6). However, our explanations concerning the strong association of cystathionine 384 
with non-cancer non-cardiovascular related prognosis are speculative and more research is 385 
certainly required to pinpoint the exact underlying mechanisms.  386 
 387 
Conclusions 388 
Elevated plasma cystathionine is a predictor of death among patients with either suspected or 389 
verified coronary heart disease. Our data should motivate further research on the trans-390 
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Table 1. HRs (95% CIs) for mortality by quartiles of plasma cystathionine among patients with stable angina pectoris1 
  
Quartiles of  plasma cystathionine 
 
 
  1  2  3  4  Per 1-SD2 
n 
 
765  789  733  746  
 
Total death           
 Incidence rate3 
 
12.2  19.4  22.2  32.5  
 
 Unadjusted   
 
1  1.60 (1.25, 2.06) <0.001  1.83 1.43,2.35)  <0.001  2.77 (2.18, 3.51)     <0.001  1.43 (1.34,1.53)      <0.001 
 Model 1 
 
1  1.34 (1.04,1.73) 0.02  1.32 (1.03,1.70) 0.03  1.74 (1.36, 2.21)      <0.001                1.23 (1.14,1.32)      <0.001 
 Model 2 
 







   
 
 Incidence rate3 
 
4.4  8.8  10.4  16.6   
 




2.00 (1.34,2.99) 0.001 
 
2.36 (1.59, 3.50) <0.001 
 
3.87 (2.67,5.63)                 <0.001
 
1.52 (1.38,1.68)                 <0.001 
 Model 1 
 
1  1.65 (1.10, 2.46)   0.02  1.64 (1.10, 2.44) 0.02  2.30 (1.57,3.37)                   <0.001  1.29 (1.16,1.44)                    <0.001









Non-cardiovascular death             
  Incidence rate3  7.8  10.5  11.8  15.9    
  Unadjusted    1  1.38 (0.99,1.90) 0.06  1.54 (1.11, 2.12) 0.01  2.14 (1.57, 2.91)                 <0.001  1.35 (1.22,1.48)                 <0.001 
  Model 1  1  1.17 (0.85,1.63) 0.34  1.14 (0.82,1.58) 0.43  1.40 (1.02,1.92)                      0.04  1.17 (1.05,1.29)                      0.004
 Model 2   1  1.24 (0.85,1.80) 0.26  1.18 (0.81,1.71) 0.39  1.42 (0.99, 2.05)                     0.06  1.16 (1.03,1.31)                  0.01 
1HRs and 95% CIs were estimated by Cox regression. Model 1 was adjusted for age and sex. Model 2 was adjusted for model 1 and for body 
mass index, hypertension, diabetes, smoking, previous acute myocardial infarction, serum total cholesterol, and treatment with folic acid or 
vitamin B6 
2Log-transformed. 






Table 2. HRs (95% CIs) for mortality by quartiles of plasma cystathionine among patients with acute myocardial infarction1 
  
Quartiles of  plasma cystathionine 
 
 
  1  2  3  4  Per 1-SD2 
n 
 
874  974  921  901  
 
Total death           
 Incidence rate3 
 
15.7  23.5  33.7  57.1  
 
 Unadjusted   
 
1  1.51 (1.17, 1.94) <0.001  2.16 (1.69, 2.75)  <0.001  3.65 (2.90, 4.59)                 <0.001  1.57 (1.48,1.68)                 <0.001 
 Model 1 
 
1  1.27 (0.98,1.63) 0.07  1.34 (1.05, 1.71) 0.02  1.88 (1.49, 2.38)                    <0.001  1.28 (1.19,1.37)                    <0.001 
 Model 2 
 







   
 
 Incidence rate3 
 
9.2  13.3  20.1  37.2   
 




1.44 (1.03, 2.00) 0.03 
 
2.16 (1.57, 2.96) <0.001 
 
3.94 (2.93,  5.29)                 <0.001
 
1.64 (1.52, 1.77) <0.001 
 Model 1 
 
1  1.20 (0.86, 1.67)   0.29  1.32 (0.96, 1.82) 0.09  1.97 (1.46, 2.67)                                      <0.001  1.33 (1.22, 1.45) <0.001 









Non-cardiovascular death             
  Incidence rate3  6.5  10.3  13.6  19.8    
  Unadjusted    1  1.61 (1.09, 2.38) 0.02  2.15 (1.48, 3.14) <0.001  3.21 (2.23, 4.62)                 <0.001  1.46 (1.32, 1.63)                                 <0.001
 Model 1  1  1.37 (0.93, 2.03) 0.11  1.36 (0.93, 1.99) 0.12  1.73 (1.19, 2.51)                      0.004  1.19 (1.06, 1.34)                                           0.003
 Model 2   1  1.28 (0.86, 1.93) 0.22  1.29 (0.86, 1.92) 0.21  1.53 (1.03, 2.26)                                       0.04  1.13 (0.99, 1.28)                                  0.06
1HRs and 95% CIs were estimated by Cox regression. Model 1 was adjusted for age and sex. Model 2 was adjusted for model 1 and for body 
mass index, hypertension, diabetes, smoking, previous acute myocardial infarction, serum total cholesterol, and treatment with folic acid or  
vitamin B6 
2Log-transformed. 






Table 3. HRs (95% CIs) for cancer and other non-cardiovascular mortality by quartiles of plasma cystathionine among patients with 
stable angina pectoris and acute myocardial infarction1 
  
Quartiles of  plasma cystathionine 
 
 
  1  2  3  4  Per 1-SD
2 
Patients with SAP         
n 
 
765  789  733  746  
 
Cancer death           
 Incidence rate3 
 
4.3  6.3  6.6  7.4  
 
 Unadjusted   
 
1  1.48 (0.96, 2.72) 0.08   1.55 (1.01,2.39) 0.05  1.75 (1.14, 2.69)     0.01  1.22 (1.07, 1.40)      0.004 
 Model 1 
 
1  1.26 (0.82, 1.94) 0.29  1.16 (0.75, 1.80) 0.49  1.16 (0.75, 1.79)      0.51  1.05 (0.91, 1.22)      0.51 
 Model 2 
 
1  1.24 (0.76,2.03) 0.39  1.23 (0.75, 2.03) 0.41  1.25 (0.76, 2.06)      0.38  1.07 (0.91, 1.27)      0.39 
Other non-cardiovascular death           
Incidence rate3  3.4  4.2  5.1  8.5    
 Unadjusted    1  1.24 (0.75, 2.05) 0.39   1.51 (0.93, 2.46) 0.09  2.64 (1.68, 4.14)     <0.001  1.49 (1.31, 1.71)      <0.001 





 Model 2  1  1.21 (0.69, 2.14) 0.50  1.10 (0.62, 1..95) 0.74  1.61 (0.94, 2.74)      0.08  1.24 (1.05, 1.48)      0.01 
Patients with AMI               
n  874  974  921  901    
Cancer death            
  Incidence rate3  4.2  5.6  7.6  9.3    
  Unadjusted    1  1.35 (0.82, 2.23) 0.24  1.86 (1.15, 3.00) 0.01  2.29 (1.15, 3.70)                 0.001  1.29 (1.11, 1.51)                 0.001 
 Model 1  1  1.16 (0.70, 1.92) 0.55  1.22 (0.75, 1.98) 0.44  1.31 (0.80, 2.36)                      0.28  1.06 (0.89, 1.25)                      0.50
 Model 2   1  1.12 (0.67, 1.88) 0.67  1.14 (0.69, 1.89) 0.61  1.29 (0.78, 2.15)                     0.32  1.05 (0.88, 1.25)                  0.62 
Other non-cardiovascular death 
          
Incidence rate3  2.3  4.7  6.0  10.6    
  Unadjusted    1  2.10 (1.12, 3.95) 0.02  2.71 (1.46, 5.02) 0.002  4.91 (2.73, 8.81)                 <0.001  1.67 (1.44, 1.93)                 <0.001 
 Model 1  1  1.76 (0.93, 3.31) 0.08  1.63 (0.87, 3.05) 0.13  2.46 (1.35, 4.47)                      0.003  1.35 (1.15, 1.59)                      <0.001














1HRs and 95% CIs were estimated by Cox regression. Model 1 was adjusted for age and sex. Model 2 was adjusted for model 1 and for body 
mass index, hypertension, diabetes, smoking, previous acute myocardial infarction, serum total cholesterol, and treatment with folic acid or  
vitamin B6. AMI, acute myocardial infarction; SAP, stable angina pectoris 
2Log-transformed. 





Table 4. The association between plasma cystathionine per SD (log transformed) and all-cause mortality according to subgroups of 
traditional risk factors and plasma B-vitamin status1 
Medications 
     Patients with SAP       
 
    Patients with AMI       
 n  Incidence rate2    HR (95% CI)  P-value  Pint 
 















< median  1463  10.2 1.15 (0.99, 1.35)  0.08  0.26 
 
1750  9.8 1.28 (1.06, 1.54)  0.01  0.11 
≥ median  1570  32.4 1.24 (1.14, 1.35)  <0.001  
  
















   Females  699  16.8 1.37 (1.15, 1.62)  <0.001  0.25 
 
962  35.9 1.30 (1.16, 1.46)  <0.001  0.48 
   Males  2334  22.5 1.20 (1.10, 1.30)  <0.001    
 
2708  29.9 1.27 (1.16, 1.38)  <0.001    
BMI                   
     No   1367  23.0 1.29 (1.16, 1.43)  <0.001  0.51  1824  35.8 1.29 (1.18, 1.42)  <0.001  0.62 
     Yes  1666  19.6 1.17 (1.06, 1.30)  0.003     1836  26.7 1.23 (1.10, 1.36)  <0.001    
Diabetes                    





     Yes  978  24.9 1.28 (1.14, 1.45)  <0.001     359  58.2 1.35 (1.14, 1.60)  <0.001    
Hypertension                    
 No  1591  17.5 1.17 (1.04, 1.31)  0.01  0.53  2581  26.4 1.32 (1.21, 1.45)  <0.001  
0.21 
 Yes  1442  25.4 1.26 (1.14, 1.39)  <0.001    1050  43.9 1.19 (1.06, 1.34)  0.003  
Smoking                    
 No  2054  20.5 1.32 (1.21, 1.44)  <0.001  0.001  1794  37.3 1.30 (1.18, 1.42)  <0.001  
0.25 
 Yes  978  22.7 1.06 (0.93, 1.21)  0.36    1876  26.1 1.24 (1.11, 1.39)  <0.001  
PLP                   
 <median  1511  25.6 1.32 (1.20, 1.45)  <0.001  0.01  1831  39.2 1.31 (1.20, 1.43)  <0.001  
0.51 
 ≥ median  1522  16.9 1.09 (0.97, 1.23)  0.12    1839  24.1 1.22 (1.09, 1.37)  <0.001  
Cobalamin                   
 <median  1270  21.7 1.21 (1.08, 1.36)  0.001  0.37  1802  33.9 1.23 (1.12, 1.36)  <0.001  0.43 
 ≥ median  1273  18.1 1.26 (1.12, 1.43)  <0.001    1803  27.5 1.33 (1.20, 1.48)  <0.001   
Folate                    
 <median  1518  22.3 1.29 (1.17, 1.44)  <0.001  0.11  1813  34.6 1.24 (1.12, 1.36)  <0.001  0.65 












1HRs and 95% CI were reported for per SD increment of plasma cystathionine and estimated by Cox hazards model, adjusted for age, and sex. AMI, 
acute myocardial infarction;  BMI, body mass index;  PLP, pyridoxal phosphate; SAP, stable angina pectoris;  
2Presented as events per1000 patient-years 





Legends for figures 
Figure 1. Associations of plasma cystathionine with baseline clinical relevant covariates. 
Spearman's rho of ranked values of the plasma cystathionine concentrations with important 
continuous covariates at baseline are reported for SAP (n=3033) and AMI (n=3670) patients, 
respectively. ADMA indicates asymmetric dimethylarginine; AMI, acute myocardial 
infarction; BMI, body mass index; CRP, C‐reactive protein; eGFR, estimated glomerular 
filtration rate; HDL, high‐density lipoprotein cholesterol; LDL, low‐density lipoprotein 
cholesterol; SAP, stable angina pectoris; TG, triglycerides. *P<0.05; **P<0.01; ***P<0.001. 
Figure 2. Dose–response relationship between log-transformed plasma cystathionine and 
the partial hazard of all-cause, cardiovascular and non-cardiovascular mortality. 
Generalized additive regression models are adjusted for age and sex in patients with SAP 
(n=3033) and AMI (n=3670). The shaded area surrounding solid lines show 95% confidence 
intervals. Density plots show the distributions of plasma cystathionine and vertical lines 
denote the 25th, 50th, and 75th, 90th percentiles, respectively. AMI, acute myocardial 
infarction; CVD, cardiovascular disease; SAP, stable angina pectoris.  
